TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18775652
Drug: Cortisol and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol and dexamethasone treatment after stimulation with phytohemagglutinin in responders
Study: 18775652
Drug: Cortisol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol treatment in responders
Study: 18775652
Drug: Cortisol and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol and dexamethasone treatment in responders
Study: 12712826
Drug: Cefoperazone 2
Normalized name: cefoperazone 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone 2 x 1.0 g i.v. daily (group I = 20 persons)
Study: 12712826
Drug: Azithromycin 1
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1 x 0.5 g (group II = 20 persons)
Study: 9103292
Drug: 25,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25,000 IU retinol daily for 5 years
Study: 9103292
Drug: 5-10 mg
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-10 mg isotretinoin daily for 3 years
Study: 8397560
Drug: Moderate-fiber dose
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-fiber dose (40 to 60 gm)
Study: 8397560
Drug: High-fiber dose
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber dose (70 to 80 gm)
Study: 22182258
Drug: Probiotic chewing
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic chewing gum containing L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289
Study: 16643581
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg haloperidol in 500 mL of normal saline
Study: 16643581
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of normal saline (placebo)
Study: 16643581
Drug: Relapse after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse after treatment
Study: 12826040
Drug: Intravenous ZD9331
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ZD9331 (n=30), on days 1 and 8 of a 3‐week cycle
Study: 12826040
Drug: Intravenous gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gemcitabine (n=25), once a week for 7 weeks followed by a 1‐week rest, then on days 1, 8 and 15 of a 4‐week cycle
Study: 31331907
Drug: Exubera (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exubera (insulin human [rDNA origin], inhaled powder)
Study: 31331907
Drug: Other diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other diabetes treatments (control)
Study: 21227540
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous metoclopramide
Study: 21170697
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg EPs 7630 daily
Study: 21170697
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg EPs 7630 daily
Study: 21170697
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg EPs 7630 daily
Study: 17191265
Drug: Standard olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard olanzapine tablets
Study: 12005078
Drug: Heptavalent CRM197
Normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent CRM197 pneumococcal conjugate vaccine (PCV)
Study: 7659241
Drug: Low-cost, technician-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-cost, technician-administered anxiety reduction intervention (removing heart rate feedback, cognitive distraction, controlled breathing techniques)
Study: 57448
Drug: Oestrogen treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen treatment for five years
Study: 57448
Drug: Delayed onset
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Oncet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed onset of oestrogen treatment (3 to 6 years)
Study: 31035474
Drug: Tomato Nutrient
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato Nutrient Complex (TNC) 15 mg lycopene
Study: 31035474
Drug: Tomato Nutrient
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato Nutrient Complex (TNC) 30 mg lycopene
Study: 31035474
Drug: Tomato Nutrient
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato Nutrient Complex (TNC) 5 mg lycopene
Study: 31035474
Drug: Synthetic lycopene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic lycopene 15 mg
Study: 23863812
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg and Valsartan 160 mg
Study: 23863812
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg and placebo
Study: 23863812
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg and placebo
Study: 21592232
Drug: Tadalafil 5mg
Normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 5mg daily for 12 weeks
Study: 21592232
Drug: Solifenacin 5mg
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin 5mg daily for 12 weeks
Study: 19628740
Drug: Serum concentrations
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum concentrations of L
Study: 12807578
Drug: Recreational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational therapy (C)
Study: 10969220
Drug: Continuous nebulization
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nebulization of salbutamol (15 mg during the first hour and 12.5 mg over the next 5 hours)
Study: 10969220
Drug: Intermittent nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nebulization of salbutamol (5 mg every 20 minutes during the first hour and 2.5 mg hourly over the next 5 hours)
Study: 1535588
Drug: Dopamine (D)
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (D) and Glyceroltrinitrate (G)
Study: 6387965
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 50 mg + Sotalol (STL) 320 mg
Study: 30264419
Drug: Behavioural activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural activation therapy
Study: 30264419
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help therapy
Study: 23352379
Drug: Sitagliptin 25
Normalized name: SITagliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 25 mg daily
Study: 23352379
Drug: Glipizide (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (initiated with 2.5 mg daily, titrated up to 10 mg twice daily)
Study: 18548148
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in daily sodium intake of 1840 mg/day
Study: 18548148
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in dietary sodium from 1200 mg/day to 2400 mg/day
Study: 16570051
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 10,000‐20,000 IU three times weekly plus best standard treatment (BST)
Study: 16570051
Drug: Best standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best standard treatment (BST) only
Study: 12755663
Drug: Conventional antipsychotics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotics, olanzapine, risperidone
Study: 11761770
Drug: 5,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU of retinyl palmitate and 30 mg of beta-carotene daily during pregnancy; 200,000 IU of retinyl palmitate at delivery
Study: 23183528
Drug: Sofosbuvir 100
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir 100 mg + PegIFN/RBV
Study: 23183528
Drug: Sofosbuvir 200
Normalized name: sofosbuvir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 200 mg + PegIFN/RBV
Study: 23183528
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg + PegIFN/RBV
Study: 14603503
Drug: Untreated drug
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated drug
Study: 10710409
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of ferrous sulfate (S) per day for 6 weeks
Study: 8229720
Drug: Topical 0.03%
Normalized name: tacrolimus topical 0.03% topical ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.03% flurbiprofen sodium
Study: 3101821
Drug: Respiratory health
Normalized name: HERBAL RESPIRATORY HEALTH CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory health worker visits (monthly by a respiratory nurse)
Study: 27592092
Drug: Severe renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe renal dysfunction (GFR ≤30 mL/min)
Study: 27592092
Drug: Moderate renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate renal dysfunction (GFR 31 to 60 mL/min)
Study: 27592092
Drug: None/mild renal
Approvals — FDA: no, EMA: no, PMDA: no
Description: None/mild renal dysfunction (GFR >60 mL/min)
Study: 24015965
Drug: Weekly Sealed
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly Sealed (WS) pedometer group
Study: 24015965
Drug: Daily Sealed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Sealed (DS) pedometer group
Study: 2467983
Drug: Nalbuphine hydrochloride
Normalized name: Nalbuphine Hydrochloride
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine hydrochloride (0.375, 0.75, 1.5, 3 and 6 mg)
Study: 2467983
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (0.1 and 0.2 mg)
Study: 2467983
Drug: Hydromorphone hydrochloride
Normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone hydrochloride (4 and 8 mg)
Study: 322672
Drug: Carpipramine 3
Normalized name: carpipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carpipramine 3 X 50 mg per day for 8 weeks
Study: 30367519
Drug: Omega-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA supplementation (2,120 mg eicosapentaenoic acid/600 mg docosohexaenoic acid)
Study: 23151431
Drug: Short-term androgen
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term androgen suppression (STAS) with leuprorelin (22.5 mg every 3 months)
Study: 23151431
Drug: Intermediate-term androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-term androgen suppression (ITAS) with leuprorelin (22.5 mg every 3 months)
Study: 23151431
Drug: ITAS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITAS plus zoledronic acid (4 mg every 3 months)
Study: 18545204
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (25-g supplement)
Study: 16190917
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg donepezil daily for 4 weeks
Study: 16190917
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg donepezil daily for 8 weeks
Study: 16190917
Drug: Post-drug discontinuation
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-drug discontinuation
Study: 7777104
Drug: Erythropoietin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin therapy without iron supplementation (Group 3)
Study: 7777104
Drug: Erythropoietin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin therapy with iron supplementation (Group 4)
Study: 111943
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat load (100 g triglyceride) alone
Study: 111943
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat load (100 g triglyceride) plus intravenous glucose infusion (0.7 g/kg/h)
Study: 111943
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose infusion (0.7 g/kg/h)
Study: 26156921
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea gargling solution (30 cc, gargled every 6 hours for 24 hours)
Study: 26156921
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water gargling (30 cc, gargled every 6 hours for 24 hours)
Study: 23354336
Drug: 0.7 g·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g·kg(‐1) mannitol (group L)
Study: 23354336
Drug: 1.4 g·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g·kg(‐1) mannitol (group H)
Study: 20850351
Drug: Intraoperative S(+)‐ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative S(+)‐ketamine (0.5 mg/kg as a preincisional bolus followed by a continuous infusion 400 μg/kg/h)
Study: 20850351
Drug: Perioperative parexocib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Perioperative parexocib (40 mg before extubation and 12 hours postoperatively)
Study: 20850351
Drug: Ropivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine alone (subpleural paravertebral infusion)
Study: 19252905
Drug: Sodium ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ibuprofen (512 mg, equivalent to 400 mg ibuprofen acid)
Study: 19252905
Drug: Ibuprofen/poloxamer (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/poloxamer (400 mg ibuprofen acid and 120 mg poloxamer 407)
Study: 19252905
Drug: Sodium ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ibuprofen
Study: 19252905
Drug: Ibuprofen/poloxamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/poloxamer
Study: 19252905
Drug: Sodium ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ibuprofen and Ibuprofen/poloxamer
Study: 17203352
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg given 30 min to 1 hour before biopsy
Study: 17203352
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg given immediately after biopsy
Study: 15879863
Drug: Doxazosin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (0.5 mg)
Study: 9623433
Drug: Propofol 6
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 6 mg kg‐1 h‐1
Study: 8151903
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for patients with clinically significant LV systolic dysfunction (LV ejection fraction <40%)
Study: 8151903
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for patients with LV dysfunction and normal LV ejection fraction (diastolic dysfunction)
Study: 3045470
Drug: 5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Gy fractional dose
Study: 27171537
Drug: Perceptive rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceptive rehabilitation treatment with Surfaces for Perceptive Rehabilitation (Su‐Per)
Study: 27171537
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group physical therapy treatment
Study: 22188731
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose extrafine BDP/F 100/6 μg (1 actuation)
Study: 22188731
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose extrafine BDP/F 100/6 μg (4 actuations)
Study: 10992535
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose inhaled steroids plus low dose theophylline (LDT, 400 mg daily)
Study: 10992535
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose inhaled steroids (LDS, 200 microgram BDP twice daily)
Study: 10992535
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose inhaled steroids (HDS, 500 microgram BDP)
Study: 6318647
Drug: Postoperative chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy, radiotherapy, or a combination of both (95% of patients treated according to a randomized trial)
Study: 27009278
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation 5 g/day for 8 weeks
Study: 27009278
Drug: Coconut oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oil (CO) control 5 g/day for 8 weeks
Study: 24293371
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of blood cholesterol lowering drugs during resistance exercise training
Study: 16027408
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for 4 days
Study: 16027408
Drug: Extended-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxybutynin chloride 10 mg/d
Study: 16027408
Drug: Extended-release tolterodine
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tolterodine tartrate 4 mg/d
Study: 11684077
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of micronised fenofibrate
Study: 9848522
Drug: Soy-protein powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-protein powder at 0, 5, 10, and 20 g/d (0-36 mg isoflavones)
Study: 8017467
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg once daily at night
Study: 25399847
Drug: Dual Antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual Antiplatelet Therapy Study participants
Study: 11393342
Drug: Imidapril 5-20
Normalized name: imidapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 5-20 mg
Study: 11393342
Drug: Hydrochlorothiazide 12.5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5-50 mg
Study: 3176834
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg/kg i.m. as premedication 45 min before induction with midazolam 0.3 mg/kg i.v. (Group 1)
Study: 3176834
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg/kg i.m. as premedication 45 min before induction with thiopentone 4 mg/kg (Group 2)
Study: 3176834
Drug: Calculated i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated i.v. administration curve
Study: 4753236
Drug: Oxprenolol 40
Normalized name: oxprenolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 40 mg oral tablet
Study: 31965548
Drug: Carotegrast methyl
Normalized name: Carotegrast methyl
DrugBank: Carotegrast methyl (DB16119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotegrast methyl (240, 480, or 960 mg)
Study: 21304925
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment of malaria (IPTc) with sulphadoxine pyrimethamine plus amodiaquine
Study: 17090282
Drug: Placebo-to-tegaserod (switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-to-tegaserod (switched from placebo to tegaserod 6 mg b.i.d.)
Study: 15612887
Drug: SCM‐III 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCM‐III 10 mL t.i.d
Study: 11035353
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally 48 hours before operation
Study: 11035353
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally 24 hours before operation
Study: 8640072
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous thymopentin (TP5) treatment, 1 g three times a week for three patients, 1 g daily for three patients, 2 g daily for two patients
Study: 8640072
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous thymopentin (TP5) treatment
Study: 1597660
Drug: Bifidobacterium bifidum
Normalized name: Bifidobacterium Bifidum
DrugBank: Bifidobacterium bifidum (DB16538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium bifidum and Lactobacillus acidophilus (Infloran) administered in capsules (two capsules 4 times per day) for 28 days
Study: 1597660
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in the same posology for 28 days
Study: 2996156
Drug: Low-dose corticotrophin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticotrophin (ACTH)
Study: 23129742
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) followed by surgery and postoperative radiotherapy
Study: 21999189
Drug: Double-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose group (40 mg/Kg TA before and after CPB)